Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

被引：0
|
作者：
Tony S. Mok
Ying Cheng
Xiangdong Zhou
Ki Hyeong Lee
Kazuhiko Nakagawa
Seiji Niho
Alka Chawla
Rafael Rosell
Jesus Corral
Maria Rita Migliorino
Adam Pluzanski
Kay Noonan
Yiyun Tang
Malaika Pastel
Keith D. Wilner
Yi-Long Wu
机构：
[1] Chinese University of Hong Kong,State Key Laboratory of Translational Oncology, Department of Clinical Oncology
[2] Jilin Provincial Cancer Hospital,Chungbuk National University Hospital
[3] First Affiliated Hospital of Third Military Medical University,Pulmonary Oncology Unit
[4] Chungbuk National University College of Medicine,Guangdong Lung Cancer Institute
[5] Kindai University Hospital,undefined
[6] National Cancer Center Hospital East,undefined
[7] SFJ Pharmaceuticals®,undefined
[8] Catalan Institute of Oncology,undefined
[9] Hospital Universitario Virgen del Rocio,undefined
[10] San Camillo-Forlanini Hospital,undefined
[11] Maria Sklodowska-Curie National Research Institute of Oncology,undefined
[12] Pfizer Inc.,undefined
[13] Pfizer Oncology,undefined
[14] Pfizer Oncology,undefined
[15] Guangdong General Hospital and Guangdong Academy of Medical Sciences,undefined
来源：
Drugs | 2021年 / 81卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：257 / 266
页数：9
相关论文
共 50 条
  • [41] First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea
    Kim, Mi-Hyun
    Choi, Chang Min
    Lee, Sung Yong
    Park, Cheol Kyu
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Chan Kwon
    Lee, Sang Hoon
    Jang, Seung Hun
    Yoon, Seong Hoon
    Jang, Tae Won
    ANTICANCER RESEARCH, 2022, 42 (03) : 1615 - 1622
  • [42] Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population
    Nakagawa, Kazuhiko
    Matsumura, Koichi
    Scory, Tayler
    Farris, Megan S.
    Larkin-Kaiser, Kelly A.
    Kikkawa, Hironori
    Ivanova, Jasmina I.
    Wilner, Keith D.
    FUTURE ONCOLOGY, 2021, 17 (01) : 103 - 115
  • [43] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [44] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [45] Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
    Zhang, Longfeng
    Li, Na
    Liu, Maobai
    Zheng, Bin
    Wu, Zhijuan
    Cai, Hongfu
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4263 - 4270
  • [46] First-line gefitinib (IRESSA) versus vinorelbine (invite): A randomized phase II study in elderly patients with advanced non-small-cell lung cancer
    Crino, L.
    Zatlouka, P.
    Reck, M.
    Pesek, M.
    Thompson, J. C.
    Forc, H. E. R.
    Ghiorghiu, S.
    Duffield, E. L.
    Armour, A.
    Cullen, M.
    ANNALS OF ONCOLOGY, 2007, 18 : 21 - 22
  • [47] First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
    Huang, L. -y.
    Chang, H. -p.
    Chang, R. -y.
    Tai, H. -y.
    Huang, Y. -w.
    Lee, P. -c.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (20) : 7632 - 7640
  • [48] Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Cheng, Ying
    Murakami, Haruyasu
    Yang, Pan-Chyr
    He, Jianxing
    Nakagawa, Kazuhiko
    Kang, Jin Hyoung
    Kim, Joo-Hang
    Wang, Xin
    Enatsu, Sotaro
    Puri, Tarun
    Orlando, Mauro
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) : 3258 - +
  • [49] CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
    Kang, Liping
    Mai, Jianliang
    Liang, Weiting
    Zou, Qihua
    Huang, Caiwen
    Lin, Yongbin
    Liang, Ying
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
    Westerink, Lotte
    Nicolai, Jelmer L. J.
    Samuelsen, Carl
    Smit, Hans J. M.
    Postmus, Pieter E.
    Griebsch, Ingolf
    Postma, Maarten J.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (06): : 931 - 943
12345